March 21, 2025 07:16 AM EDTUpdated 08:43 AM
Pharma
Manufacturing

John­son & John­son ear­marks $55B to boost US ca­pac­i­ty 

Anna Brown

News Reporter

John­son & John­son is plan­ning to in­vest $55 bil­lion to build up its US foot­print over the next four years, be­com­ing the lat­est phar­ma com­pa­ny …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

TRENDING NOW

Bridge­Bio, Ed­i­tas fi­nance chiefs de­part; For­mer FDA No. 2 joins Re­cur­sion's board

As­traZeneca broad­ens pres­ence in Chi­na, promis­ing $8B+ to Har­bour and Syneron

Ex­clu­sive: Roivant-backed Van­tAI de­buts AI mod­el Neo-1, tak­ing ‘the big next step’ af­ter Al­phaFold 3

Up­dat­ed: FDA ap­proves Al­ny­lam’s Amvut­tra in AT­TR-CM, kick­ing off com­pe­ti­tion with Pfiz­er, Bridge­Bio

No­vo Nordisk says new ear­ly R&D struc­ture will ‘fu­ture-proof’ its busi­ness

Gen­fit's up to €185M roy­al­ty deal; J&J’s Trem­fya gets a Crohn's ap­proval

A service from the Financial Times